Brett P. Monia - 20 Dec 2023 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Chief Executive Officer, Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Issuer symbol
IONS
Transactions as of
20 Dec 2023
Net transactions value
-$49,060
Form type
4
Filing time
22 Dec 2023, 19:11:23 UTC
Previous filing
18 Dec 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $307,710 +6,500 +5.5% $47.34 124,611 20 Dec 2023 Direct
transaction IONS Common Stock Sale $322,643 -6,500 -5.2% $49.64 118,111 20 Dec 2023 Direct F1
transaction IONS Common Stock Options Exercise $828,450 +17,500 +15% $47.34 135,611 21 Dec 2023 Direct
transaction IONS Common Stock Sale $862,577 -17,500 -13% $49.29 118,111 21 Dec 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -6,500 -27% $0.000000 17,500 20 Dec 2023 Common Stock 6,500 $47.34 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -17,500 -100% $0.000000* 0 21 Dec 2023 Common Stock 17,500 $47.34 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $49.90 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.11 to $49.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.